Ramaswamy's Roivant Inks $650M R&D Deal With This Tiny Diabetes Biotech Post author:Sam Post published:February 11, 2018 Post category:BioPharma With the deal in hand, Roivant has stepped into the world of metabolic diseases. Source: BioSpace You Might Also Like Massachusetts' Biostage Slashes 71% of Staff, Evaluating Strategic Alternatives October 12, 2017 Intuitive Surgical Reports New Employee Option Grants For June 2017 June 8, 2017 Daiichi Sankyo Abandons 6 Clinical Programs in Q1 Update May 10, 2017
